A recent study published in Diabetes Technology & Therapeutics has highlighted the promising off-label use of semaglutide and tirzepatide in treating type 1 diabetes (T1D). The study found that these medications significantly reduced HbA1c levels and body weight in adults with T1D, offering a potential breakthrough in the management of the condition.
The findings suggest that these treatments could address longstanding challenges in T1D care, particularly the lack of pharmacologic options beyond insulin. According to GlobalData, a leading pharma analytics firm, these results open up new possibilities for improving both glycemic control and managing obesity in T1D patients.
Semaglutide, the key component in Novo Nordisk’s diabetes drug Ozempic and weight management medication Wegovy, and tirzepatide, featured in Eli Lilly’s Mounjaro and obesity treatment Zepbound, have already proven successful in the treatment of type 2 diabetes and obesity. Both drugs have generated billions in sales, contributing to significant market growth for their respective companies.
These new findings could pave the way for expanding their use into the type 1 diabetes market, offering a novel approach to a disease traditionally dominated by insulin therapy.
Related topics:
Anti-Obesity Drugs Show Benefits for Kidney Transplant Recipients with Type 2 Diabetes
Early Menopause Linked to Increased Risk of Type 2 Diabetes, Study Finds
Building Lifelong Connections Through Diabetes Support Groups
